ARA-290 10mg

Description

ARA-290 (Cibinetide) is an 11-amino acid peptide modeled on the helix B surface of erythropoietin, engineered to selectively activate the Innate Repair Receptor (IRR) — a tissue-protective receptor distinct from the classical erythropoietic EPO receptor — without triggering red blood cell production.

Research Overview

The characterization of the IRR as a distinct signaling complex (EPO receptor / common beta chain heterodimer) motivated development of ARA-290 as a selective tool for accessing its anti-inflammatory and neuroprotective pathways. Studies in models of painful diabetic neuropathy have demonstrated significant reductions in symptom scores at 28 days. The SARA trial examined ARA-290 in sarcoidosis patients with small fiber neuropathy, documenting improvements in corneal nerve fiber density — a quantifiable marker of peripheral nerve integrity. Mechanistic studies have characterized downstream signaling through Akt and ERK pathways following IRR activation. Preclinical models of ischemia, traumatic injury, and metabolic inflammation have each been examined in the published literature. Research teams continuing investigation in this space use ARA-290 as a selective tool for parsing IRR-specific tissue protection from broader EPO signaling, with active interest in peripheral neuropathy and organ-protective models.

Key References

• Brines M et al. (2014). ARA 290 Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes. Molecular Medicine.
• Gonçalves MB et al. (2021). Cibinetide increases corneal nerve fiber density in sarcoidosis-associated small nerve fiber loss and neuropathic pain. EClinicalMedicine.
• Brines M, Cerami A. (2012). The receptor that tames the innate immune response. Molecular Medicine. [PubMed Search]